Nan Fung Group Holdings’s Xenon Pharmaceuticals XENE Stock Holding History

Nan Fung Group Holdings’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-158,605	Closed	-$5.32M	–	33
2025 Q1	$5.32M	Buy	158,605 +51,925	+49%	+$1.97M	4.34%	9
2024 Q4	$4.18M	Hold	106,680	–	–	3.58%	11
2024 Q3	$4.2M	Hold	106,680	–	–	3.62%	10
2024 Q2	$4.16M	Hold	106,680	–	–	4.44%	8
2024 Q1	$4.59M	Hold	106,680	–	–	4.26%	7
2023 Q4	$4.91M	Hold	106,680	–	–	3.06%	7
2023 Q3	$3.64M	Sell	106,680 -7,700	-7%	-$288K	2.95%	8
2023 Q2	$4.4M	Hold	114,380	–	–	2.81%	8
2023 Q1	$4.09M	Hold	114,380	–	–	2.79%	8
2022 Q4	$4.51M	Hold	114,380	–	–	3.11%	7
2022 Q3	$4.13M	Hold	114,380	–	–	2.64%	8
2022 Q2	$3.48M	Sell	114,380 -83,500	-42%	-$2.53M	2.39%	8
2022 Q1	$6.05M	Hold	197,880	–	–	2.87%	9
2021 Q4	$6.18M	Hold	197,880	–	–	1.83%	11
2021 Q3	$3.02M	Hold	197,880	–	–	0.97%	15
2021 Q2	$3.69M	Buy	+197,880	New	+$3.65M	1.15%	9

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nan Fung Group Holdings's XENE Position: Q2 2025 in Review

Nan Fung Group Holdings sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 158,605 shares — an estimated $5.32M sold.

Nan Fung Group Holdings first reported a position in XENE in Q2 2021 and held it in 16 quarters. The position peaked at $6.18M in Q4 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

Nan Fung Group Holdings reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Nan Fung Group Holdings sold 158,605 Xenon Pharmaceuticals shares in Q2 2025, an estimated $5.32M.
Nan Fung Group Holdings first reported a position in Xenon Pharmaceuticals in Q2 2021 and held it in 16 quarters.
Nan Fung Group Holdings's Xenon Pharmaceuticals position peaked at $6.18M in Q4 2021.
206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Nan Fung Group Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.